High serum total concentration of matrix metalloproteinase-9 (pro-MMP-9 and MMP-9) in patients with systemic sclerosis;Wysokie całkowite stȩżenie metaloproteazy macierzy 9 (pro-MMP-9 i MMP-9) w surowicy krwi chorych na twardzinȩ układowa̧

Przeglad Dermatologiczny

Volumn 92, Issue 3, 2005, Pages 217-223

  Bogaczewicz, Jarosław ^a   Krasowska, Dorota ^a   Stryjecka Zimmer, Marta ^b   Chodorowska, Grazyna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b NONE   (Poland)

Author keywords

Extracellular matrix; Matrix metalloproteinases; MMP 9; Systemic sclerosis; Tissue inhibitors of metalloproteinases

Indexed keywords

GELATINASE B;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; IMMUNE SYSTEM; MICROVASCULATURE; SYSTEMIC SCLEROSIS; TURNOVER TIME;

EID: 22444439618     PISSN: 00332526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Błaszczyk M., Jarza̧bek-Chorzelska M., Jabłonska S. i inni: Autoantibodies to nucleolar antigens in systemic scleroderma: clinical correlations. Br J Dermatol 1990, 123, 421-430.
2. Black C.M.: The aetiopathogenesis of systemic sclerosis. J Intern Med 1993, 234, 3-8.
3. Mauch C., Eckes B., Hunzelmann N. i inni: Control of fibrosis in systemic scleroderma. J Invest Dermatol 1993, 100, 92-96.
4. Bogaczewicz J., Chodorowska G., Krasowska D.: Rola metaloproteaz macierzy i tkankowych inhibitorów metaloproteaz w gojeniu sic ran skóry. Przegl Dermatol 2004, 91, 253-261.
5. Bogaczewicz J., Chodorowska G., Krasowska D.: Rola metaloproteaz macierzy i tkankowych inhibitorów metaloproteaz w progresji nowotworów skóry a nowe strategie farmakologicznej inhibicji metaloproteaz macierzy. Przegl Dermatol 2004, 91, 153-160.
6. Bogaczewicz J., Chodorowska G., Krasowska D.: Rola metaloproteaz macierzy i tkankowych inhibitorów metaloproteaz w starzeniu siȩ słonecznym skóry. Przegl Dermatol 2004, 91, 163-168.
7. Kuroda K., Shinkai H.: Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997, 289, 567-572.
8. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23, 581-590.
9. LeRoy E.G., Black C., Fleischmajer R. i inni: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15, 202-205.
10. Clements P.J., Lachenbruch P.A., Seibold J.R. i inni: Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993, 20, 1892-1896.
11. Steen V.D., Powell D.L., Medsger TA. In Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988, 31, 196-203.
12. Steen V.: Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003, 62, 97-99.
13. Medsger TA Jr, Silman A.J., Steen V.D. i inni: A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999, 26, 2159-2167.
14. Bogaczewicz J., Chodorowska G., Krasowska D.: Rola metaloproteaz macierzy i tkankowych inhibitorów metaloproteaz w twardzinie układowej. Przegl Dermatol 2003, 90, 373-381.
15. Takeda K., Hatamochi A., Ueki H. i inni: Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 1994, 103, 359-363.
16. Bou-Gharios G., Osman J., Black C. i inni: Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis. Clin Chim Acta 1994, 231, 69-78.
17. Sato S., Hayakawa I., Hasegawa M. i inni: Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003, 120, 542-547.
18. Fakhoury H., Hillarby M.C., Weiss J.B.: Increased gelatinase activity in systemic sclerosis dermal fibroblast cultures with unaltered gelatinase A mRNA expression. J Dermatol Sci 2002, 29, 62-69.
19. Toubi E., Kessel A., Grushko G. i inni: The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol 2002, 20, 221-224.
20. Kikuchi K., Kubo M., Hoashi T. i inni: Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis. Clin Exp Dermatol 2002, 27, 301-305.
21. Bogaczewicz J., Krasowska D., Stryjecka-Zimmer M. i inni: Wysokie stȩżenia tkankowego inhibitora metaloproteaz-1 (TIMP-1) w surowicy krwi chorych na twardzinȩ układowa̧ - zwia̧zek z obecnościa̧ zmian narza̧dowych. Przegl Dermatol 2004, 91, 467-474.
22. Bogaczewicz J., Chodorowska G., Krasowska D.: Rola metaloproteaz macierzy i tkankowych inhibitorów metaloproteaz w układzie odpornościowym skóry. Przegl Dermatol 2005, 92, 139-149.
23. Opdenakker G., Van den Steen P.E., Van Damme J.: Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001, 22, 571-579.
24. Needleman B.W., Wigley F.M., Stair R.W.: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992, 35, 67-72.
25. Kahaleh M.B., Yin T.G.: Enhanced expression of high-affinity interleukin-2 receptors in scleroderma: possible role for IL-6. Clin Immunol Immunopathol 1992, 62, 97-102.
26. Hasegawa M., Fujimoto M., Kikuchi K. i inni: Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997, 24, 328-332.
27. Bruns M., Hofmann C., Herrmann K. i inni: Serum levels of soluble IL-2 receptor, soluble ICAM-1, TNF-alpha, interleukin-4 and interleukin-6 in scleroderma. J Eur Acad Dermatol Venereol 1997, 8, 222-228.
28. Sopata I., Dancewicz A.M.: Presence of a gelatin-specific proteinase and its latent form in human leucocytes. Biochim Biophys Acta 1974, 370, 510-523.
29. Yu Q., Stamenkovic I.: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000 14, 163-176.
30. Gearing A.J., Beckett P., Christodoulou M. i inni: Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994, 370, 555-557.
31. Schonbeck U., Mach F., Libby P.: Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998, 161, 3340-3346.
32. Sheu B.C., Hsu S.M., Ho H.N. i inni: A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001, 61, 237-242.
33. Van den Steen P.E., Proost P., Wuyts A. i inni: Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000, 96, 2673-2681.
34. McQuibban G.A., Butler G.S., Gong J.H. i inni: Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001, 276, 43503-43508.